Multiple Sclerosis Research Repository

1. CADTH Canadian Drug Expert Committee Recommendation (Final) for Ocrelizumab (Ocrevus)

-Indication: Treatment of adult patients with relapsing-remitting multiple sclerosis with active disease defined by clinical and imaging features

-the incremental clinical benefits and risks in comparison with other available disease-modifying therapies for RRMS are uncertain

-there was no statistically significant difference between ocrelizumab and interferon beta-1a for change from baseline in the MSFC (multiple sclerosis functional composite) in OPERA-I

-The statistical testing hierarchy had been stopped before the evaluation of NEDA in both OPERA-I and OPERA-II

-2 network meta-analyses suggested that there were no differences among any of the DMTs included in the analyses

-The submitted model lacked transparency and was unnecessarily complex.  This made it challenging to assess validity and to conduct the reanalyses

-CDP estimates based on a 12-week confirmation period (CDP-12) may be a poor indicator of permanent disease worsening for a long-term condition.  Use of a 24-week CDP estimate may be more reflective of clinical outcomes over an annual cycle